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Abstract
The human immunodeficiency virus (HIV) protease is a homodimeric aspartyl
protease that is crucial for the viral life-cycle, cleaving proviral polyproteins, hence
creating mature protein components that are required for the formation of an
infectious virus. With diagnostic measures and clinically used protease inhibitors
focusing on HIV-1, due to its higher virulence and prevalence, studies of the
efficacy of those inhibitors on HIV-2 protease remain widely lacking. Utilizing a wild-
type HIV-2 vector backbone and cloning techniques we have developed a cassette
system where the efficacy of clinically used protease inhibitors can be studied for
various serotypes of HIV-2 protease both in enzymatic and cell culture assays. In
our experiments, optimization of the expression protocol led to a relatively stable
enzyme, for cell culture assays, the efficiency of transfection and transduction
capability of the modified vector was tested and was not found to differ from that of
the wild-type, moreover, a 2nd generation protease inhibitor was used to
demonstrate the usefulness of the system. The combination of assays performed
with our cassette system is expected to provide an accurate measure of the efficacy
of currently used; as well as experimental protease inhibitors on HIV-2.
Background
The human immunodeficiency virus (HIV) is the causative agent of acquired
immune deficiency syndrome (AIDS) that had claimed the lives of millions
worldwide. Bearing a striking genomic resemblance to HIV-1, HIV-2 harbors a
distinct clinical feature in that it is less infectious, less pathogenic and has a much
lower rate of progression into AIDS [1]; moreover, HIV-2 has a much lower
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prevalence than its counter-part and has been localized mainly in a region
confined to Western Africa. All those features have led to protease inhibitors (PIs)
being designed specifically for HIV-1, with the majority of studies focusing on the
efficacy of those inhibitors in association with HIV-1 protease, assuming that the
inhibitors might have equal efficacy on both proteases [2], and that inadvertently
had led to a scarcity in the field of studies of those inhibitors in association with
HIV-2 protease. Molecular clock analysis studies have traced the origin of HIV-2
to the region of Guinea-Bissau as a result of an evolution from the simian
immunodeficiency virus/sooty mangabeys [3]. So far eight groups of HIV-2 have
been described in the literature and designated alphabetical letters A-H [4–6] with
groups A and B gaining a wide international spread whereas the other subtypes
remain relatively constrained in the West African region. The ending of the
colonial era, population migration and international trade have all been
implicated in the worldwide spread of HIV-2, especially in Europe, with countries
such as France and Portugal reporting the incidence of HIV-2 being continuously
on the rise [7, 8], while a slow decline in prevalence in West Africa being
attributed to the low pathogenicity of HIV-2 has been observed [9–12].
Similar to that of HIV-1, HIV-2 protease is also a homodimeric aspartyl
enzyme that is comprised of two identical monomers, each containing 99 amino
acid residue, playing a vital role in the HIV life-cycle through processing of Gag
and Gag-Pro-Pol precursor polyproteins leading to viral maturation. The
literature describes a 39–48% similarity of amino acid sequences between HIV-1
and HIV-2 proteases [2, 13], depending on the virus subtype being studied. This
polymorphism greatly affects the specificity of the protease for peptide substrates
and inhibitors, hence leading to drug resistance [14–16], and may render an
otherwise very potent inhibitor on HIV-1 protease obsolete. Despite the seemingly
significant sequence differences between HIV-1 and -2 protease, the major
structural elements around the active site remain highly conserved [13], and PI-
associated mutations in HIV-2 having relatively high frequency are perhaps
natural polymorphisms in their respective strains [17].
In comparison to HIV-1, fewer studies have examined the efficacy of clinically
used protease inhibitors on HIV-2, moreover, researches have focused on either
enzymatic [18] or in vitro cell culture studies on protease inhibitors in regards to
HIV-2 [15, 19, 20], and significantly different IC50 and Ki results can be obtained
in these assays. In kinetic assays, the results are highly influenced by the level of
purity and degree of stability of the enzyme, results obtained from in vitro cell
culture experiments on the other hand, are dependent on the nature of assay used
and the types of cells under study. In addition, even a slight variation in the
protease coding sequence may alter the results dramatically due to a variation of
folding and stability of the enzyme; hence the use of different protease sequences
may yield variable results. The lack of a standardized protocol to examine the
efficacy of protease inhibitors remains as a hindrance in the analysis, therefore,
development of a cassette system that facilitates the analysis of the potency of
protease inhibitors on the same protease coding sequence both in kinetic and in
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vitro cell culture assays will greatly aid the determination of the PI’s efficacy, and
may help the design of inhibitors being more potent on HIV-2 protease.
Materials and Methods
HIV-2 vector system
The vector system is composed of HIV-2CGP as a structural protein expression
construct, CRU5SINCGW a minimal HIV-2 vector with GFP expression cassette
and pMD.G vector, coding for the envelope protein of vesicular stomatitis virus.
HIV-2CGP and CRU5SINCGW were a kind gift from Joseph P. Dougherty at the
Robert Wood Johnson Medical School [21].
Cassette construction
HIV-2CGP protease coding sequence was used as template: 5’- CCT CAA TTC
TCT CTT TGG AAA AGA CCA GTA GTC ACA GCA TAC ATT GAG GGT CAG
CCA GTA GAA GTT TTG TTA GAC ACG GGA GCT GAC GAC TCA ATA GTA
GCA GGA ATA GAG TTA GGA AAC AAT TAT AGC CCA AAA ATA GTA GGG
GGA ATA GGG GGA TTC ATA AAT ACC AAG GAA TAT AAA AAT GTA GAA
ATA GAA GTT CTA AAT AAA AAG GTA CGG GCC ACC ATA ATG ACA GGC
GAC ACC CCA ATC AAC ATT TTT GGC AGA AAT ATT CTG ACA GCC TTA
GGC ATG TCA TTA AAT CTA -3’. Site-directed mutagenesis was done according
to QuikChange mutagenesis protocol (Stratagene, La Jolla, CA, USA), utilizing
designed oligonucleotide primers: 5’-CTC TCT TTG GAA AAG ACC GGT AGT
CAC AGC ATA C-3’ and 5’-GGC AGA AAT ATT CTG ACA GCG CTA GGC
ATG TCA TTA AAT CTA C-3’ to introduce unique restriction sites AgeI and AfeI
at 59 and 39 of the CGP protease coding region, respectively. The silent mutations
were 8 amino acids apart from the ends of the protease coding sequence. NdeI and
BamHI restriction sites were then attached to its 59 and 39 end respectively using
PCR with the aid of designed oligonucleotides: 5’-CTT CAT ATG CCT CAA TTC
TCT CTT TGG AAA AGA CCG G-3’ and 5’-CGA TCC GTA CAG TAA TTT AGA
TAC TCC TAG GGC G-3’. The entire region was then ligated into a pET11a
expression plasmid (Invitrogen) for bacterial expression. Success of the
mutagenesis and ligation were verified by restriction endonuclease enzyme
digestion and DNA sequencing.
293T cell transfection and transduction
In accordance with an HIV-1 transfection protocol [22], 293T human embryonic
kidney cells (Invitrogen) were seeded in T75 flask in 15 ml Dulbecco’s Modified
Eagle’s Medium (DMEM) (Sigma-Aldrich) supplemented with 10% fetal bovine
serum (FBS), 1% glutamine and 1% penicillin-streptomycin. The day before the
transfection, cells were passaged in order to achieve 70% confluency the next day.
At 70% confluency (5266106 cells/ml) a total of 45 mg plasmid DNA was used
for the transfection of cells using Polyethylenimine. Cells were then incubated at
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37 C˚, 5% CO2 in 5 ml 1% FBS containing DMEM without antibiotics. After
6 hours, the medium was replaced by 15 ml DMEM containing 10% FBS, 1%
glutamine, 1% penicillin-streptomycin. The medium was then collected after 24,
48 and 72 hours, filtered through a 0.45 mm polyvinylidene fluoride filter
(Millipore) and concentrated by ultracentrifugation (100000 g, 2 hours, 4 C˚). The
pellet containing viral particles was then dissolved in 200 ml phosphate-buffered
saline (PBS) and stored at 270 C˚. ELISA based colorimetric reverse transcriptase
assay (Roche) was then used to detect the amount of reverse transcriptase (RT) in
the viral samples.
Regarding the infectivity (transduction) assay, 293T cells were plated in 96-
wells plate in 200 ml DMEM supplemented with 10% FBS, 1% glutamine and 1%
penicillin-streptomycin. At 50% confluency (2.5236104 cells/ml), cells in 50 ml
DMEM were infected with viral particles containing 57 ng reverse transcriptase as
determined by the reverse transcriptase colorimetric assay per well. On the next
day the medium was supplemented with 120 ml of DMEM containing 20% FBS,
2% glutamine, 2% penicillin-streptomycin and then the cells were incubated at
37 C˚, 5% CO2 for 6 days. Cells were then scraped off and fixed in PBS containing
1% formaldehyde. Infected cells were then checked under fluorescence
microscope (Axiom 200) for the presence of green fluorescent protein (GFP). For
quantitative analysis the cells were counted by flow cytometry (FACS Calibur, BD
Bioscience) to determine the percentage of GFP positivity in 5000 cells.
In vitro protease expression and purification
The protease ligated into pET11a was expressed in a culture of 100 ml of E. coli
BL21(DE3) (Invitrogen) cells in Luria-Bertani medium supplemented with
100 mg/ml ampicillin. Culture was then induced at 0.8–1.0 OD600nm with a final
concentration of 1 mM isopropyl-B-D-1-thiogalactopyranoside for 3 hours. Cells
were harvested by centrifugation at 5500 g (Beckman centrifuge, JA-14 rotor),
20 minutes, 4 C˚ and the pellet was stored at 4 C˚ overnight. The following day the
pellet was dissolved in 8 ml buffer A (50 mM tris-hydroxymethyl aminomethane
(Tris), 10 mM dithiothreitol (DTT), 10 mM ethylenediaminetetraacetic acid
(EDTA), pH 8.0), after the addition of 4 mg of lysozyme the cells were disrupted
using the sonication method (Branson Sonicator, 363 minutes at 40% energy,
4 C˚) and then centrifuged at 48000 g (JA-20 rotor) for 20 minutes at 4 C˚ (step 1).
The pellet was re-suspended in 8 ml buffer B (50 mM Tris, 10 mM DTT, 10 mM
EDTA, 1 M urea, 0.5% Triton X-100, pH 8.0) followed by another centrifugation
(step 2). On the following step the pellet was re-suspended in 8 ml buffer A and a
repeat centrifugation was carried (step 3). The insoluble fraction was then
solubilized in 5 ml buffer C (50 mM Tris, 10 mM DTT 5 mM EDTA, 7.5 M
guanidine-HCl, pH 8.0) (step 4) [23]. The protease was then purified from this
fraction using reversed-phase high performance liquid chromatography with the
aid of an A¨KTA purifier (Amersham Pharmacia Biotech) using a POROS 20 R2
(PE Biosystems, PerSeptive Biosystems) C18 column. A linear gradient from
99.95% water and 0.05% trifluroacetic acid (TFA) to 40% acetonitril and 0.05%
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TFA over a period of 25 minutes was applied at a flow rate of 1 ml/min at room
temperature. Following the elution, the peak fractions were immediately
lyophilized with eppendorf concentrator plus and then solubilized in buffer D
(20 mM piperazine-1, 4-bis(2-ethanesulfonic acid) (PIPES), 1 mM EDTA,
100 mM NaCl, 10% glycerol, 0.5% Nonident P40, pH 7.0) then pooled. The
pooled fraction was dialyzed against the same buffer overnight and then
concentrated using Amicon Ultra-4 centrifugal filter units (Millipore). Protein
concentration of fractions was determined by the Bradford assay (Bio-Rad).
Activity measurement
The activity of the protease was measured using an HPLC-based method utilizing
an oligopeptide substrate MSLNLPVAKV as described previously [24]. The
reaction contained 10 ml buffer E (0.5 M phosphate, 10 mM DTT, 4 M NaCl,
10% glycerol, pH 5.6), 5 ml substrate (2 mg/ml) dissolved in water and 5 ml
purified protease. The reaction mixtures were incubated for 1 hour at 37 C˚, then
the reaction was stopped by the addition of 180 ml 1% TFA and product and
substrate peaks were separated by using a water-acetonitrile gradient in the
presence of 0.05% TFA. Active site titration was performed as described [25]
using darunavir as a potent inhibitor and the HPLC method.
Inhibitory effect of darunavir
Following the verification of the enzyme activity, the second generation protease
inhibitor darunavir (NIH AIDS Reagent Program) was used to test our modular
system. Serial dilutions were prepared from the inhibitor using dimethyl sulfoxide
(DMSO) in concentrations ranging from 10 nM to 50 mM, the catalytic reactions
contained 10 ml buffer E, 4.8 ml substrate, 5 ml purified protease and 0.2 ml
inhibitor, followed by incubation at 37 C˚ for 1 hour. The concentration of the
protease was adjusted to achieve less than 20% substrate hydrolysis. Reactions
were terminated by the addition of 180 ml 1% TFA, thereafter HPLC
measurements were used to determine the inhibitor’s IC50 by measuring the
decrease in substrate hydrolysis. The inhibitory constant Ki was then calculated
from IC50 using the formula Ki5 (IC50- E/2)/(S/Km+1), in which E is the active
enzyme concentration, S is the substrate concentration and Km is the Michaelis
constant.
In the cell culture experiments, 293T cells in T75 flask were transfected using
the protocol mentioned above. After 5-6 hours incubation at 37 C˚, cells were split
and transferred into a 96-wells plate containing serial dilutions of darunavir
ranging from 0.05–100 mM in a total volume of 200 ml DMEM/well supplemented
with 10% FBS, 1% glutamine and 1% penicillin-streptomycin. After 3 days
incubation at 37 C˚, the virus containing medium was collected from the wells,
briefly centrifuged to remove cellular debris, and 10 ml samples were taken from
each corresponding well. Reverse transcriptase colorimetric assay was then used to
calculate the IC50 from triplicate measurements. It is necessary to mention that in
HIV-2 Protease Cassette System
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order to get accurate results using the colorimetric assay, a slight modification to
the manufacturer’s protocol was needed, such as the incubation of samples with
reaction mixture for 17–18 hours, to allow for sufficient detection and
quantification of reverse transcriptase.
Study of autodegradation/autoinactivation
To examine the stability of the purified protease and its susceptibility to
autodegradation, the active protease dialyzed at 4 C˚ against buffer D (pH 7.0) was
incubated at 37 C˚ for various time intervals and the remaining activity was
measured as described for the activity assays. Similar experiments were carried out
with purified protease dialyzed in 50 mM Na-acetate and 50 mM NaCl, (pH 5.0)
[23]. For SDS-polyacrylamide gel analysis, 15 ml of protease was incubated at 37 C˚
for multiple time intervals, then run on 16% SDS gel, densitometry was then used
to determine the density of the different protease bands using AlphaImager HP
system software.
Results and Discussion
In this paper, we present an HIV-2 cassette system that renders the study of the
HIV-2 protease possible both in in vitro kinetic and cell culture studies for
comparative analysis. Utilizing a ROD strain based HIV-2 lentiviral vector system
(Figure 1), unique silent restriction sites were introduced into the protease coding
region 8 amino acids apart from the termini that allows for the interchange of
different protease coding segments (Figure 2). Analysis of HIV-2 protease
sequences have shown that the majority of strains harboring treatment-associated
resistance mutations comprise a single or multiple amino acid changes that fall
within that region [17, 26], therefore, the positioning of the silent restriction sites
will allow for the extensive study of those mutations and their role in the
susceptibility to PIs. Having optimized the transfection and transduction
protocols in the cell culture experiments, we have achieved more than 87%
transfection and 25% transduction efficiency as measured by flow cytometry
detecting GFP positive cells (Figure 3).
Calculation of viral titers by multiplying the cell number, the percentage of GFP
and the dilution factor from transduction experiments yielded infectious unit/ml
(IU/ml) of 2.26106 for the wild-type, and 1.836106 for the modified vector,
those results fall within the expected transduction efficiency of HIV-2 derived SIN
vectors in adherent cell lines [21, 27]. It is also noteworthy that the percentage of
positive GFP cells was related directly to the concentration of recombinant virus
used. In our experiments, transduction was merely used as a measure to compare
the modified vector to the wild-type, the 20–25% efficiency was calculated as the
percentage of GFP positive cells detected by flow cytometry, as a result of using
the same concentration of viruses to transduce 293T cells in a 96-wells plate.
HIV-2 Protease Cassette System
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The vector used is an HIV-2 based self-inactivating vector, due to alterations of
the LTR regions. As a result, there is a loss of transcriptional activity following
genome integration into target cells, rendering the virus capable of only a single
round of replication, therefore, due to the fact that the viral protease is essential to
the processing of the viral polyproteins in the late stage of infection, inhibition
profiling of protease inhibitors was performed in the virus production stage, using
reverse transcriptase as a measurement to detect the efficacy of the PI. To support
our methodology, previous studies had shown that the protease is required for the
full activity of the reverse transcriptase [28], thus, using protease inhibitors at this
stage is expected to result in the formation of immature, non-infectious virus
particles, with decreased RT activity; depending on the concentration of PI used.
Levels of RT can then be detected by the reverse transcriptase colorometric assay,
and provide a valid IC50 values for various PIs.
In single cycle phenotypic assays, commonly, either luciferase activity or GFP
fluorescence can be measured after infection of target cells, alternatively, RT
activity can be quantified from the supernatant, as a measure of mature, infectious
particles [15, 21, 29]. We chose to detect RT since it is a significantly more
sensitive measure as compared to GFP fluorescence.
To provide a purified enzyme for the kinetic analysis, the protease from the
CGP plasmid was amplified and ligated into the expression vector pET11a. After
Figure 1. Vectors used for 293T cell transfection. A: HIV-2CGP, a CMV driven gag-pol expression construct. B: CRU5SINCGW, HIV-2 based minimal
vector with a GFP expression cassette. C: pMD.G a plasmid coding for VSV envelope protein. CMV: human cytomegalovirus immediate early promoter; SD:
splice donor site; rre: rev response element. BGHpA: bovine growth hormone polyadenylation signal. U3-R-U5; retroviral long terminal repeats. cppt; central
polypurine tract. GFP; green fluorescence protein. WPRE; woodchuck hepatitis virus post-transcriptional regulatory element. VSV-G; vesicular stomatitis
virus G protein. PolyA; polyadenylation site.
doi:10.1371/journal.pone.0113221.g001
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expression in E. coli, the protease was purified using HPLC with the aid of a C18
column (Figure 4). To determine the activity of the purified protease, it was
incubated with an oligopeptide substrate MSLNLQPVAKV representing the
protease/reverse transcriptase cleavage site in HIV-2 (arrow marks the site of
cleavage) and HPLC was used to analyze the cleavage products as described
previously [24]. Following the confirmation of the activity of the enzyme,
measurements were then performed to determine the kinetic parameters. The
obtained values Km50.012 (¡0.002) mM, kcat50.91 (¡0.02) s
21, kcat/Km575.8
(¡12.7) mM21s21 were very similar to those previously determined for a
chemically synthesized, wild-type enzyme, refolded using the same protocol [24].
Based on the protein content and activity of the protease samples, the folding
efficiency was approximated to be 10–15%. In order to demonstrate the usefulness
of the modular system, a second generation PI (darunavir) was used for kinetic
and cell culture inhibition, HPLC measurements performed in triplicates were
used to determine the IC50 which was found to be 0.002 (¡0.0001) mM that is
equivalent to Ki50.05 (¡0.005) nM values, while experiments done in vitro using
cultured cells yielded an IC50 of 0.42 (¡0.05) mM (Figure 5). These results are in
the same range with those found in previous studies [18], other experiments
Figure 2. Schematic representation of the cassette system. HIV-2 protease can be interchanged between the lentiviral HIV-2CGP vector and the in vitro
pET11a expression plasmid, utilizing the unique restriction sites. Protease sequence: P Q F S LW K R * P V V TAY I E G Q P V E V L L D T G A D D S I VA
G I E L G N N Y S P K I V G G I G G F I N T K E Y K N V E I E V L N K K V R AT I M T G D T P I N I F G R N I LT * A L G M S L N L. The asterisks indicate the
beginning and end of the cassette.
doi:10.1371/journal.pone.0113221.g002
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Figure 3. Flow cytometric detection of green fluorescent protein. A: number of gated cells following transfection using wild-type HIV-2 vector. B: number
of gated cells following transfection with the vector modified for the cassette system. C: transduction using wild-type vector. D: transduction using the
modified vector. A minimum of three experiments were carried and the data shown are representative samples of results acquired. Pink color indicates
control cells.
doi:10.1371/journal.pone.0113221.g003
Figure 4. SDS-polyacrylamide gel electrophoresis (16%). A: supernatants 1, 2, 3, 4 obtained from steps 1-
4 following expression in BL21(DE3) cells. 15 ml of supernatant was run on 16% SDS-polyacrylamide gel, the
asterisk indicates the solubilized pellet after 15x dilution with water to assist visualization. B: protease
fractions after reversed-phase high performance liquid chromatography, arrows indicate the pooled fractions.
doi:10.1371/journal.pone.0113221.g004
HIV-2 Protease Cassette System
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conducted solely on cell culture yielded slightly different values that maybe a
result of using different culture cells or the type of assay used [19].
Autoproteolysis of the HIV proteases is best described as a process by which the
protease domain facilitates a cascade of proteolytic reactions that ultimately lead
to the dissociation of the free mature protease that in turn cleaves different
peptide sequences in the Gag and Gag-Pol polyproteins [30]. Following its
dissociation, this autolytic ability of the viral protease also plays a major role in its
autodegradation. It is thought that this degradation occurs initially at an exposed
amino-terminal strand/loop that is likely to be exposed to the protease in case of
HIV-1/2 and SIV [31]. Autodegradation is a major factor in the attributed loss of
activity of the viral enzyme, a process that had proven to be a major hindrance in
the expression and purification of the enzyme. Methods aimed at decreasing the
autodegradation have been used such as the use of catalytic-site inhibitors, storing
the protease at a suboptimal pH, or modifying the implicated amino acid cleavage
sites (Leu5-Trp6 in case of HIV-1), which has been found to be more resistant to
autodegradation in HIV-2 [31].
In our activity analysis of the protease, we have found that incubation in a
buffer having a neutral pH greatly decreases its autodegradation/autoinactivation,
as evident from our comparative analysis with incubation in an acidic (pH 5.0)
buffer that was typically used previously to dialyze HIV proteases. When the
activity of the enzyme was monitored, the protease in the buffer having neutral
pH maintained almost half of its activity after a 24 hour incubation period at 37
˚
C, in contrast to incubation at pH 5.0, which yielded minimal activity after only
12 hours of incubation (Figure 6). As the SDS-gel analysis did not show
substantial protein degradation following either refolding protocol, the loss of
enzymatic activity appears to be majorly the consequence of autoinactivation
rather than autodegradation. We also found that the immediate lyophilization
and storage in a pH 7.0 buffer after reversed-phase chromatography aided greatly
in the preservation of its activity, and facilitated the prolonged storage and studies
on the purified fractions (data not shown).
Figure 5. Inhibitory effect of darunavir. A: IC50 determination in vitro using HPLC. B: IC50 determination in cell culture. Activity percentage is plotted on the
Y axis versus logarithmic transformation of the inhibitor’s concentration (mM).
doi:10.1371/journal.pone.0113221.g005
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The success of this modular system in testing the efficacy of darunavir both in
kinetic and in cell culture assays has only paved the way for future measurements
of currently widely used protease inhibitors, given the absence of a standardized
protocol and the antigenic variability of clinical isolates. We hope that the
development of this cassette system and the optimization of the protease
expression may aid in the thorough analysis of HIV-2 protease and its
susceptibility to protease inhibitors in clinical use.
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